Limits...
CXCL1 is elevated in the urine of bladder cancer patients.

Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H - Springerplus (2015)

Bottom Line: Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009).These results indicate that CXCL1 is elevated in BCa when compared to non-cancer subjects, but lacks robustness as a standalone urinary biomarker.Additional studies into CXCL1 may shed more light on the role of CXCL1 in BCa tumorigenesis as well as ramifications of therapeutically targeting CXCL1.

View Article: PubMed Central - PubMed

Affiliation: John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813 USA.

ABSTRACT
Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), regulate tumor epithelial-stromal interactions that facilitate tumor growth and invasion. Recently, several studies have linked CXCL1 expression to bladder cancer (BCa). In this study, we aimed to determine if increased levels of urinary CXCL1 were found in BCa patients. Voided urines from 86 subjects, cancer subjects (n = 43), non-cancer subjects (n = 43) were analyzed. The protein concentration of CXCL1 was assessed by enzyme-linked immunosorbent assay (ELISA). CXCL1 concentration level was normalized using urinary protein and urinary creatinine concentrations. We used the area under the curve of a receiver operating characteristic (AUROC) to investigate the performance of CXCL1 in detecting BCa. Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Urinary CXCL1 possessed a sensitivity of 55.81 %, specificity of 83.72 %, positive predictive value of 77.42 %, negative predictive value of 65.46 %, and an overall accuracy of 69.77 % (AUROC: 0.7015, 95 % CI 0.5903-0.8126). These results indicate that CXCL1 is elevated in BCa when compared to non-cancer subjects, but lacks robustness as a standalone urinary biomarker. Additional studies into CXCL1 may shed more light on the role of CXCL1 in BCa tumorigenesis as well as ramifications of therapeutically targeting CXCL1.

No MeSH data available.


Related in: MedlinePlus

Comparison of urine concentrations of CXCL1 between a the cancer and non-cancer groups, b low-grade and high-grade BCa and c low stage (NMIBC) and high stage BCa (MIBC). Data are normalized to urinary creatinine. Horizontal lines depict median levels. Significance (p < 0.05) was assessed by the Wilcoxon rank sum test
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4628002&req=5

Fig1: Comparison of urine concentrations of CXCL1 between a the cancer and non-cancer groups, b low-grade and high-grade BCa and c low stage (NMIBC) and high stage BCa (MIBC). Data are normalized to urinary creatinine. Horizontal lines depict median levels. Significance (p < 0.05) was assessed by the Wilcoxon rank sum test

Mentions: The cohort of 86 subjects consisted of 43 subjects with active BCa and 43 control subjects. Demographic, clinical, and pathologic characteristics of both groups are illustrated in Table 1. In the cancer cohort, VUC had a sensitivity of only 51 %. Due to the unavoidable variability of voided urine with respect to total volume and time within the bladder, CXCL1 was normalized to urinary creatinine. Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Though the mean urinary CXCL1 concentrations were elevated in high grade vs. low-grade disease (229.5 ± 430.2 vs. 69.3 ± 112.0 pg/mg, respectively p = 0.9170) and high-stage vs. low-stage disease (253.1 ± 412.6 vs. 133.2 ± 345.9 pg/mg, respectively p = 0.2862), the results were not significant. ELISA data are depicted in Fig. 1.Table 1


CXCL1 is elevated in the urine of bladder cancer patients.

Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H - Springerplus (2015)

Comparison of urine concentrations of CXCL1 between a the cancer and non-cancer groups, b low-grade and high-grade BCa and c low stage (NMIBC) and high stage BCa (MIBC). Data are normalized to urinary creatinine. Horizontal lines depict median levels. Significance (p < 0.05) was assessed by the Wilcoxon rank sum test
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4628002&req=5

Fig1: Comparison of urine concentrations of CXCL1 between a the cancer and non-cancer groups, b low-grade and high-grade BCa and c low stage (NMIBC) and high stage BCa (MIBC). Data are normalized to urinary creatinine. Horizontal lines depict median levels. Significance (p < 0.05) was assessed by the Wilcoxon rank sum test
Mentions: The cohort of 86 subjects consisted of 43 subjects with active BCa and 43 control subjects. Demographic, clinical, and pathologic characteristics of both groups are illustrated in Table 1. In the cancer cohort, VUC had a sensitivity of only 51 %. Due to the unavoidable variability of voided urine with respect to total volume and time within the bladder, CXCL1 was normalized to urinary creatinine. Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Though the mean urinary CXCL1 concentrations were elevated in high grade vs. low-grade disease (229.5 ± 430.2 vs. 69.3 ± 112.0 pg/mg, respectively p = 0.9170) and high-stage vs. low-stage disease (253.1 ± 412.6 vs. 133.2 ± 345.9 pg/mg, respectively p = 0.2862), the results were not significant. ELISA data are depicted in Fig. 1.Table 1

Bottom Line: Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009).These results indicate that CXCL1 is elevated in BCa when compared to non-cancer subjects, but lacks robustness as a standalone urinary biomarker.Additional studies into CXCL1 may shed more light on the role of CXCL1 in BCa tumorigenesis as well as ramifications of therapeutically targeting CXCL1.

View Article: PubMed Central - PubMed

Affiliation: John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813 USA.

ABSTRACT
Chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), regulate tumor epithelial-stromal interactions that facilitate tumor growth and invasion. Recently, several studies have linked CXCL1 expression to bladder cancer (BCa). In this study, we aimed to determine if increased levels of urinary CXCL1 were found in BCa patients. Voided urines from 86 subjects, cancer subjects (n = 43), non-cancer subjects (n = 43) were analyzed. The protein concentration of CXCL1 was assessed by enzyme-linked immunosorbent assay (ELISA). CXCL1 concentration level was normalized using urinary protein and urinary creatinine concentrations. We used the area under the curve of a receiver operating characteristic (AUROC) to investigate the performance of CXCL1 in detecting BCa. Mean urinary concentrations of CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of creatinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Urinary CXCL1 possessed a sensitivity of 55.81 %, specificity of 83.72 %, positive predictive value of 77.42 %, negative predictive value of 65.46 %, and an overall accuracy of 69.77 % (AUROC: 0.7015, 95 % CI 0.5903-0.8126). These results indicate that CXCL1 is elevated in BCa when compared to non-cancer subjects, but lacks robustness as a standalone urinary biomarker. Additional studies into CXCL1 may shed more light on the role of CXCL1 in BCa tumorigenesis as well as ramifications of therapeutically targeting CXCL1.

No MeSH data available.


Related in: MedlinePlus